Trial Profile

Bortezomib, pegylated liposomal doxorubicin and dexamethasone as induction therapy prior to ASCT (autologous stem cell transplantation) with reduced intensity in elderly patients with multiple myeloma [Bortezomib, Desametasone e Doxorubicina liposomiale peghilata come terapia di induzione prima di ASCT (autologous stem cell transplantation) ad intensita ridotta in pazienti anziani affetti da mieloma multiplo]

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com